Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPATICC: Heart failure medication in advanced cancer
NCT05636774Phase 2Completed
- Sponsor
- Universitätsmedizin Essen
- Start
- Dec 2022
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sacubitril + valsartan, ivabradine, ferric carboxymaltose and empagliflozin in heart failure (HF) and Cardiac dysfunction (2 arms), sponsored by Universitätsmedizin Essen. Primary endpoint: Win ratio with hierarchical components: days alive and able to wash oneself, ability to walk 4m, self-reported patient global assessment. Started Dec 2022; status: completed.
02
Drugs
sacubitril + valsartanivabradineferric carboxymaltoseempagliflozin
03
Conditions
heart failure (HF)Cardiac dysfunction
Beyond the preview
Go deeper on NCT05636774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05636774.